Results 1 to 10 of about 11,211 (144)

Dolutegravir Is Associated With Lower Odds of Gestational Diabetes Compared to Other Antiretroviral Therapy Regimens Among Pregnant Women in India: A Cross-Sectional Analysis. [PDF]

J Int AIDS Soc
Introduction In non‐pregnant adults living with HIV, dolutegravir is associated with weight gain and increased type 2 diabetes risk. In pregnancy, data on the effect of dolutegravir on gestational diabetes (GDM) risk is inconclusive.
Chebrolu P, Ahmed F, Tambe S, Alexander M, Raichur P, Kole A, Kante S, Kulkarni V, Gupte N, Bhosale R, Naik S, Gupta A, Brown TT, Mathad JS.   +13 more
europepmc   +3 more sources

Early outcomes of South African children with persistent viral non-suppression following switch to dolutegravir-based antiretroviral therapy. [PDF]

South Afr J HIV Med
Background: Since 2019 dolutegravir-based antiretroviral therapy (ART) has been introduced for South African children and adolescents living with HIV (CALHIV), including those with persistent viral non-suppression.
Guerrini M, Maré M, Hulsman C, Greybe L, Lishman J, Edson C, Hisham T, Frigati L, Rabie H.   +8 more
europepmc   +2 more sources

Not your usual drug-induced liver injury: Dolutegravir-associated granulomatous hepatitis. [PDF]

South Afr J HIV Med
Dolutegravir is an integrase inhibitor in first-line antiretroviral therapy in South Africa. We describe a patient who developed severe drug-induced liver injury on dolutegravir-containing antiretroviral treatment, in whom liver biopsy demonstrated ...
Vally M, Ayob M, Mahomed A, Mahomed K, Mudini W, Lala V.   +5 more
europepmc   +2 more sources

Acute interstitial nephritis due to dolutegravir: The first case reported

Nefrología (English Edition), 2023
Kidney disease is frequent in HIV-patients. We present a case of a 44-year-old woman, with known uncontrolled HIV infection and chronic kidney disease due to HIV-associated nephropathy.
Rui Barata, Bernardo Marques da Costa, David Navarro, Marco Mendes, Cecília Silva, Mário Góis, Helena Sousa, Fernando Nolasco   +7 more
doaj   +3 more sources

Virological Findings and Treatment Outcomes of Cases That Developed Dolutegravir Resistance in Malawi’s National HIV Treatment Program

Viruses, 2023
Millions of Africans are on dolutegravir-based antiretroviral therapy (ART), but few detailed descriptions of dolutegravir resistance and its clinical management exist.
Hope Kanise, Joep J. van Oosterhout, Pachawo Bisani, John Songo, Bilaal W. Matola, Chifundo Chipungu, Katherine Simon, Carrie Cox, Mina C. Hosseinipour, Jean-Batiste Sagno, Risa M. Hoffman, Claudia Wallrauch, Sam Phiri, Kim Steegen, Andreas Jahn, Rose Nyirenda, Tom Heller   +16 more
doaj   +1 more source

Effect of obesity on dolutegravir exposure in Black Southern African adults living with HIV

Southern African Journal of HIV Medicine, 2022
Background: Dolutegravir, a component of the preferred first-line antiretroviral therapy regimen, has been associated with increased weight gain. South Africa has a high prevalence of obesity, especially among women.
Enkosi Mondleki, Clifford G. Banda, Nomathemba C. Chandiwana, Simiso Sokhela, Lubbe Wiesner, Francois Venter, Gary Maartens, Phumla Z. Sinxadi   +7 more
doaj   +1 more source

Dolutegravir Discontinuation for Neuropsychiatric Symptoms in People Living with HIV and Their Outcomes after Treatment Change: A Pharmacogenetic Study

Metabolites, 2022
Neuropsychiatric symptoms have been reported in patients receiving dolutegravir, a known inhibitor of the renal and neuronal-expressed organic anion transporter 2 (encoded by SLC22A2 gene). The effect of the genetic variant SLC22A2 808C>A on dolutegravir
Jessica Cusato, Alberto Borghetti, Elisabetta Teti, Maurizio Milesi, Maria Cristina Tettoni, Stefano Bonora, Mattia Trunfio, Antonio D’Avolio, Mirko Compagno, Simona Di Giambenedetto, Giovanni Di Perri, Andrea Calcagno   +11 more
doaj   +1 more source

Standard versus double dose dolutegravir in patients with HIV-associated tuberculosis: a phase 2 non-comparative randomised controlled (RADIANT-TB) trial [version 1; peer review: 2 approved]

Wellcome Open Research, 2021
Dolutegravir, a second-generation integrase strand transfer inhibitor (InSTI), is replacing efavirenz as first-line antiretroviral therapy (ART) in low middle-income countries (LMICs).
Rulan Griesel, Andrew Hill, Graeme Meintjes, Gary Maartens   +3 more
doaj   +1 more source

Community acceptability of dolutegravir-based HIV treatment in women: a qualitative study in South Africa and Uganda

BMC Public Health, 2020
Background Despite concerns about dolutegravir use in pregnancy, most low- and middle-income countries are accelerating the introduction of dolutegravir-based regimens into national antiretroviral treatment programmes.
Yussif Alhassan, Adelline Twimukye, Thoko Malaba, Catherine Orrell, Landon Myer, Catriona Waitt, Mohammed Lamorde, Andrew Kambugu, Helen Reynolds, Saye Khoo, Miriam Taegtmeyer   +10 more
doaj   +1 more source

Two-drug regimens with dolutegravir plus rilpivirine or lamivudine in HIV-1 treatment-naïve, virologically-suppressed patients: Latest evidence from the literature on their efficacy and safety

Journal of Global Antimicrobial Resistance, 2020
Objectives: In the HIV-1-positive population, a paradigm shift from three-drug regimens (3DRs) to dolutegravir-based two-drug regimens (2DRs) both as initial and switch treatment is beginning to take place, supported virologically by the availability of ...
Valeria Cento, Carlo Federico Perno
doaj   +1 more source